Ulrik Nielsen Net Worth

The estimated Net Worth of Ulrik B. Nielsen is at least $2.43 Миллион dollars as of 24 January 2022. Ulrik Nielsen owns over 14,287 units of Merrimack Pharmaceuticals Inc stock worth over $559,326 and over the last 12 years he sold MACK stock worth over $552,750. In addition, he makes $1,317,610 as Independent Director at Merrimack Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ulrik Nielsen MACK stock SEC Form 4 insiders trading

Ulrik has made over 17 trades of the Merrimack Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 14,287 units of MACK stock worth $60,577 on 24 January 2022.

The largest trade he's ever made was exercising 105,000 units of Merrimack Pharmaceuticals Inc stock on 27 May 2014 worth over $133,350. On average, Ulrik trades about 18,553 units every 120 days since 2012. As of 24 January 2022 he still owns at least 36,968 units of Merrimack Pharmaceuticals Inc stock.

You can see the complete history of Ulrik Nielsen stock trades at the bottom of the page.

Ulrik Nielsen biography

Dr. Ulrik B. Nielsen Ph.D. serves as Independent Director of the Company. He has served as a member of our board of directors since January 2015 and is one of our co-founders. Dr. Nielsen led our research and drug discovery in various roles from when he joined us in 2002 to January 2015, including as our Senior Vice President and Chief Scientific Officer from March 2009 until January 2015. Dr. Nielsen has been President and Chief Executive Officer of Tidal Therapeutics, Inc., a biotechnology company, since August 2018. Dr. Nielsen previously served in various capacities at Torque Therapeutics Inc., a biotechnology company, including as President from January 2015 to June 2018, Founder Chairman from November 2017 to June 2018 and Chief Executive Officer from January 2015 to November 2017. Dr. Nielsen also served as Chief Executive Officer of Silver Creek Pharmaceuticals, Inc., a former majority owned subsidiary of ours, from July 2010 to March 2014. Dr. Nielsen also currently serves on the board of directors of Alloy Therapeutics LLC. Dr. Nielsen holds a Ph.D. in molecular biology and an M.S. in biochemistry from the University of Copenhagen.

What is the salary of Ulrik Nielsen?

As the Independent Director of Merrimack Pharmaceuticals Inc, the total compensation of Ulrik Nielsen at Merrimack Pharmaceuticals Inc is $1,317,610. There are no executives at Merrimack Pharmaceuticals Inc getting paid more.

How old is Ulrik Nielsen?

Ulrik Nielsen is 48, he's been the Independent Director of Merrimack Pharmaceuticals Inc since 2018. There are 9 older and 2 younger executives at Merrimack Pharmaceuticals Inc. The oldest executive at Merrimack Pharmaceuticals Inc is Dr. Anthony J. Sinskey Ph.D., Sc.D., 81, who is the Co-Founder and Scientific Advisor.

What's Ulrik Nielsen's mailing address?

Ulrik's mailing address filed with the SEC is C/O MERRIMACK PHARMACEUTICALS, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE, MA, 02142.

Insiders trading at Merrimack Pharmaceuticals Inc

Over the last 13 years, insiders at Merrimack Pharmaceuticals Inc have traded over $1,152,598 worth of Merrimack Pharmaceuticals Inc stock and bought 3,978,994 units worth $28,464,218 . The most active insiders traders include Eric Western Standard Llcwe..., Robert J. Mulroy и Gary L Crocker. On average, Merrimack Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $459,997. The most recent stock trade was executed by Eric Western Standard Llcwe... on 26 December 2023, trading 49,550 units of MACK stock currently worth $651,583.

What does Merrimack Pharmaceuticals Inc do?

merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.

Complete history of Ulrik Nielsen stock trades at Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals Inc executives and stock owners

Merrimack Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Ulrik Nielsen,
  Independent Director
• Gary Crocker,
  Chairman of the Board, President, Treasurer
• Dr. Ulrik B. Nielsen,
  Co-Founder & Independent Director
• Gary L. Crocker M.B.A., MBA,
  Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
• Tim Surgenor,
  IR Contact Officer
• Russell Ray,
  Independent Director
• Noah Levy,
  Independent Director
• Eric Andersen,
  Independent Director
• Timothy R. Surgenor,
  Sec.
• Dr. Daryl C. Drummond Ph.D.,
  Head of Research
• Dr. Fazal R. Khan Ph.D.,
  Sr. VP of Manufacturing
• Ellen K. Forest,
  Head of HR
• Geoffrey Grande C.F.A.,
  Sr. Director of Communications
• Dr. Anthony J. Sinskey Ph.D., Sc.D.,
  Co-Founder and Scientific Advisor
• Ana Radeljevic,
  
• Sergio L. Santillana,
  Chief Medical Officer
• John M. Dineen,
  Director
• Yasir B. Al Wakeel,
  CFO and Head of Corp Dev
• Jeffrey A Munsie,
  General Counsel
• James H. Quigley,
  Director
• John Mendelsohn,
  Director
• William A. Sullivan,
  CFO and Treasurer
• Edward J. Stewart,
  SVP & Pres, Healthcare Sol
• Peter N Laivins,
  Head of Development
• Michael E Porter,
  Director
• Richard Peters,
  President and CEO
• Robert J. Mulroy,
  President and CEO
• Birgit M. Schoeberl,
  Head of Discovery
• Vivian S Lee,
  Director
• William M. Mc Clements,
  Head of Corporate Operations
• George Demetri,
  Director
• Thomas E. Jr. Needham,
  Chief Business Officer
• Jean M. Franchi,
  Chief Financial Officer
• Capital Management, Llcjfl ...,
  
• Lp22 Nw Fund, Lp22 Nw Fund ...,
  
• Gordon J. Fehr,
  Director
• Anthony J Sinskey,
  Director
• James Van B. Dresser,
  Director
• Sarah E Nash,
  Director
• Fazal R. Khan,
  SVP of Manufacturing
• Robert C Gay,
  Director
• Walter M Phd Lovenberg,
  Director
• Clet M. Niyikiza,
  EVP of Development
• Jason Aryeh,
  10% owner